Cynata Therapeutics Limited (AU:CYP) has released an update.
Cynata Therapeutics Limited has made notable progress in its clinical trials, with Phase 2 trials for acute graft-versus-host disease and Phase 1 trials for diabetic foot ulcers and kidney transplantation. The company’s innovative Cymerus™ MSCs have shown promise in reversing pulmonary fibrosis, and a Phase 3 trial in osteoarthritis has completed recruitment. With a cash balance of A$4.29 million, Cynata is poised for further advancements, supported by an expected R&D tax rebate.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
